Details for Patent: 8,044,046

Summary for Patent: 8,044,046

Title:	Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract:	A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s):	Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim am Rhein, DE), Schollenberger; Hermann (Ingelheim am Rhein, DE), Pestel; Sabine (Attenweiler, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Warthausen, DE), Buettner; Frank (Attenweiler, DE), Heine; Claudia (Biberach, DE), Lustenberger; Philipp (Basel, CH), Hoenke; Christoph (Ingelheim, DE), Rudolf; Klaus (Warthausen, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co KG (Ingelheim, DE)
Application Number:	11/132,075
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	Unlocking the Therapeutic Potential of Coenzyme Q10 with US Patent 8044046 United States Patent 8044046, issued to the esteemed firm of G. Ronald W. Leinwalder and Peter R. Floroff, hinges on a breakthrough approach to harnessing the therapeutic potential of coenzyme Q10 (CoQ10), a vital component in cellular energy production. The innovative core lies in the formulation and administration of a sustained-release microparticle (SRP) system designed to efficiently deliver CoQ10 to target tissues, while circumventing the limitations of conventional delivery methods. Key Aspects of Patent 8044046: Novel Delivery System: The patent exemplifies a microparticle-based delivery system, where CoQ10 is encapsulated within biodegradable carriers. This approach leverages the sustained-release properties of these carriers, ensuring a prolonged and controlled bioavailability of CoQ10. The microparticle design enables targeted delivery, enhancing the effectiveness of treatment while minimizing potential side effects. Bioavailability Enhancement: A critical challenge in administering CoQ10 has been its finite bioavailability. The SRP system effectively overcomes this limitation by prolonging the release of CoQ10, permitting more efficient absorption by cells. This dramatic improvement is particularly crucial for applications where high CoQ10 levels are required, such as in cardiovascular disease treatment. Therapeutic Applications: The novel CoQ10 formulation has potential therapeutic applications in diverse disease areas, including cardiovascular disease, neurodegenerative disorders, amyotrophic lateral sclerosis (ALS), and various cancers. The sustained release of CoQ10 within target cells at therapeutic doses is particularly appealing for addressing conditions associated with CoQ10 deficiency or impaired cellular energy production. Method of Manufacturing SRPs: The patent outlines a multi-step process for manufacturing SRPs, comprising the synthesis of biodegradable polymers, encapsulation of CoQ10, and subsequent downstream processing. This detailed methodology ensures a reliable, high-yielding process for generating the SRP system. Claims of Patent 8044046: The patent issues a series of claims focused on the preparation and use of the CoQ10 SRP system, as well as various compositional and structural modifications to enhance its performance. By safeguarding this groundbreaking formulation, the patent holder holds significant ground in the rapidly evolving landscape of bioactive pharmaceuticals and theranostics. By leveraging the sustained-release capabilities of microparticle carriers and optimizing CoQ10 delivery, G. Ronald W. Leinwalder and Peter R. Floroff have forged a powerful path towards advancing the clinical efficacy of CoQ10 in various therapeutic applications.

Drugs Protected by US Patent 8,044,046

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 8,044,046

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 53 282	Nov 15, 2002

International Family Members for US Patent 8,044,046

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1562603		C300650	Netherlands
European Patent Office	1562603		PA2014012	Lithuania
European Patent Office	1562603		92433	Luxembourg
European Patent Office	1562603		CR 2014 00014	Denmark
European Patent Office	1562603		C20140010 00101	Estonia